| 前收盘价格 | 34.44 |
| 收盘价格 | 34.00 |
| 成交量 | 1,162,589 |
| 平均成交量 (3个月) | 735,868 |
| 市值 | 1,255,482,496 |
| 预期市盈率 (P/E Forward) | 37.31 |
| 价格/销量 (P/S) | 5.86 |
| 股市价格/股市净资产 (P/B) | 31.74 |
| 52周波幅 | |
| 利润日期 | 10 Nov 2025 |
| 营业毛利率 | -10.19% |
| 营业利益率 (TTM) | -23.48% |
| 稀释每股收益 (EPS TTM) | -0.610 |
| 季度收入增长率 (YOY) | 38.30% |
| 总债务/股东权益 (D/E MRQ) | 410.02% |
| 流动比率 (MRQ) | 0.910 |
| 营业现金流 (OCF TTM) | 2.09 M |
| 杠杆自由现金流 (LFCF TTM) | -26.88 M |
| 资产报酬率 (ROA TTM) | 0.90% |
| 股东权益报酬率 (ROE TTM) | -37.31% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Drug Manufacturers - Specialty & Generic (US) | 看涨 | 混合的 |
| Drug Manufacturers - Specialty & Generic (全球的) | 看涨 | 混合的 | |
| 股票 | Harrow, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 5.0 |
| 内部交易活动 | NA |
| 价格波动 | 2.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 2.0 |
| 平均 | 2.88 |
|
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company’s FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company’s ophthalmology-focused pharmaceutical compounding business. |
|
| 部门 | Healthcare |
| 行业 | Drug Manufacturers - Specialty & Generic |
| 投资方式 | Small Growth |
| 内部持股比例 | 15.07% |
| 机构持股比例 | 57.11% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| First Turn Management, Llc | 30 Jun 2025 | 228,761 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 74.00 (B. Riley Securities, 118.10%) | 购买 |
| 中 | 67.50 (98.94%) | |
| 低 | 63.00 (BTIG, 85.68%) | 购买 |
| 平均值 | 67.67 (99.44%) | |
| 总计 | 6 购买 | |
| 平均价格@调整类型 | 45.15 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 12 Nov 2025 | 69.00 (103.36%) | 购买 | 38.44 |
| 29 Sep 2025 | 64.00 (88.62%) | 购买 | 48.40 | |
| Ladenburg Thalmann | 12 Nov 2025 | 66.00 (94.52%) | 购买 | 38.44 |
| B. Riley Securities | 01 Oct 2025 | 74.00 (118.10%) | 购买 | 48.37 |
| 23 Sep 2025 | 70.00 (106.31%) | 购买 | 48.85 | |
| BTIG | 29 Sep 2025 | 63.00 (85.68%) | 购买 | 48.40 |
| 24 Sep 2025 | 63.00 (85.68%) | 购买 | 47.88 | |
| Lake Street | 29 Sep 2025 | 70.00 (106.31%) | 购买 | 48.40 |
| Craig-Hallum | 23 Sep 2025 | 64.00 (88.62%) | 购买 | 48.85 |
该时间范围内无数据。
| 日期 | 类型 | 细节 |
|---|---|---|
| 18 Nov 2025 | 公告 | Harrow Announces Closing of Acquisition of Melt Pharmaceuticals |
| 10 Nov 2025 | 公告 | Harrow Announces Third Quarter 2025 Financial Results |
| 27 Oct 2025 | 公告 | Harrow To Report Third Quarter 2025 Financial Results After Market Close on November 10, 2025 |
| 06 Oct 2025 | 公告 | ImprimisRx Announces Leadership Changes |
| 26 Sep 2025 | 公告 | Harrow to Acquire Melt Pharmaceuticals |
| 25 Sep 2025 | 公告 | Harrow Launches Harrow Access for All (HAFA) |
| 15 Sep 2025 | 公告 | Harrow Announces Agenda and Speakers for Investor & Analyst Day |
| 08 Sep 2025 | 公告 | Harrow Announces Offering of $250.0 Million Senior Unsecured Notes Due 2030 |
| 08 Sep 2025 | 公告 | Harrow Announces Pricing of $250.0 Million Offering of Senior Unsecured Notes Due 2030 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合